The Indian Patent Office revoked Novartis' patent for Vymada, a heart failure drug, citing a lack of novelty and inventive step. This decis...

Novartis AG is set to acquire Tourmaline Bio for $1.4 billion, aiming to bolster its drug pipeline amid upcoming generic competition for ke...

InCred Asset Management is cautious about US-facing generic pharma companies due to potential tariff risks and single-digit earnings growth...

Leading brokerages are bullish on several key stocks. CLSA initiates coverage on Swiggy with a "Buy" rating, projecting a 31% upside. Jeffe...

"While the exact revenue from Entresto-related supplies is undisclosed, it contributes a meaningful share to the overall business. However,...

And, of course, the chemical in terms of the domain expertise, the kind of the chemistry skills and the overall talent pool that this count...

Top brokerages ICICI Securities, Citi, and Jefferies recommend Allied Blenders, Divi’s Laboratories, and Zomato, highlighting growth in pre...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday.

Natco filed writ petition citing procedural irregularities and violation of principles of natural justice by the Assistant Controller of Pa...

Natco has argued before Justice C Hari Shankar against the grant of patent by IPO to the pharmaceutical composition comprising combination ...

According to data from AIOCD PharmaTrac, an agency that closely tracks pharmaceutical sales, Vymada had sales of Rs 68.3 crore for December...

The pan-European FTSEurofirst 300 index, which had risen 1.3 percent in the previous session, was up 0.2 percent at 1,329.6 points by 0820 ...

The Swiss drug major said the USFDA's decision was based on results of a study on 8,442 patients, including 637 from India.